Advanced search
Start date
Betweenand

Effect of Bifidobacterium probiotics on the modulation of immune response and alveolar bone loss in an experimental periodontitis model on normoglycemic and diabetic mice

Grant number: 17/22345-0
Support type:Scholarships in Brazil - Master
Effective date (Start): March 01, 2018
Effective date (End): July 31, 2019
Field of knowledge:Health Sciences - Dentistry - Periodontology
Cooperation agreement: Coordination of Improvement of Higher Education Personnel (CAPES)
Principal Investigator:Marcia Pinto Alves Mayer
Grantee:Natali Shimabukuro
Home Institution: Instituto de Ciências Biomédicas (ICB). Universidade de São Paulo (USP). São Paulo , SP, Brazil
Associated research grant:15/18273-9 - New strategies for the control of periodontitis, AP.TEM

Abstract

Although the use of probiotics is very common, their efficacy on the prevention and control of inflammatory diseases is strain-dependent. Our previous data have shown data probiotics belonging to the genus Bifidobacterium are able to reduce the formation of a multispecies biofilm including Porphyromonas gingivalis and Streptococcus species, and to interfere on the adhesion and invasion of epithelial cells and on the response to this periodontopathogen. Periodontal diseases and diabetes are both inflammatory diseases and probiotic bacteria can be used to their control. The present study aims to evaluate the ability of probiotics of the Bifidobacterium genus to control the periodontal tissues destruction in experimental normoglycemic and diabetic animal models. Two probiotic strains, selected based on our previous in vitro data (B. breve 1101A and B. bifidum 162ª) will be tested in periodontitis animal models using normoglycemic and diabetic C57Bl mice. Periodontitis will be induced by the oral inoculation of a microbial consortium formed by capsulated and fimbriated P. gingivalis (W83 and ATCC 33277, respectively), Prevotella intermedia (clinical isolate 17) and Fusobacterium nucleatum (ATCC 25586). Diabetes will be induced by ingestion of a highlipidic/hypercaloric diet. Probiotics will be orally administered once /day everyday throughout the experimental period. After sacrifice, serum and gingival cytokines profile will be determined by ELISA, alveolar bone loss will be evaluated by microCT, T cells phenotype in gingival tissues will be determined by flow cytometry, gene expression of genes encoding intra and extra cellular receptors will be evaluated by RT-qPCR, microbioma of gingival tissue and faeces by means of high performance sequencing of 16SrRNA gene, determination of oral pathogen levels in oral biofilm, serum, feaces liver and spleen samples by quantitative PCR using a primer pair specific for the 16SrRNA gene for P. gingivalis, P. intermedia and F. nucleatum. In diabetic mice, glucose levels and insulin resistance will be determined. The mentioned strategies will provide evidence of the effects and mechanisms of selected probiotics on periodontal diseases and associated conditions. (AU)